Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America - Poli-Bigelli, S; Rodrigues-Pereira, J; Carides, A D; Aprepitant Protocol 054 Study Group (Cancer, 2003)